Navigation Links
Study Calls for Modification of CMS Conditions of Participation to Preserve Access to Life-Saving Liver Transplantations under Less than Optimal Conditions

SAN FRANCISCO, Nov. 4, 2011 /PRNewswire/ -- Adherence to strict outcome requirements imposed by the Centers for Medicare and Medicaid Services (CMS) has an adverse effect on liver transplantation centers performing life-saving liver transplantations under less than optimal conditions, according to researchers at Northwestern University. According to researcher Edward Wang, PhD, "While quality improvement initiatives aim to enhance post-transplant outcomes, the inadequately risk-adjusted criteria implemented by CMS might act as a disincentive to perform life-saving liver transplantation in high cardiovascular risk patients and limit the use of valuable donor organs of perceived lower quality."

That statement was made as part of a study that was presented on Sunday, November 6, 10:30 am, at the Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases. Researchers retrospectively examined the records of 65,601 adult recipients of deceased-donor liver transplantations performed between 1995 and 2010.

Examination of these records, which were part of the database of the Organ Procurement and Transplant Network (OPTN) of the United Network of Organ Sharing (UNOS), revealed that access to liver transplantation for high-risk patients suffers under the CMS Conditions of Participation (CoP). Specifically, researchers looked at trends in the Donor Risk Index and the recipient Cardiovascular Risk Index before and after implementation of the CoP. What they found was that 71 percent of transplant centers experienced a decline in either or both of the risk indices.

According to Dr. Wang, "Our findings suggest that regulatory oversight by the CMS on liver transplantation programs has led to the unintended consequence of risk-averse behavior by transplant centers. As a result, transplant centers under strict oversight might be reluctant to perform life-saving liver transplantation in high cardiovascular risk patients and/or to accept suboptimal donor organs.  Modification of risk adjustment, which is integral to performance measurement, is necessary to preserve access to liver transplantation among high risk recipients and sustain the optimal use of marginal donors."

The conclusion reached is that risk adjustment must be modified to preserve access to liver transplantation by high cardiovascular risk recipients and the use of marginal donor organs. "We believe that there is a need for mitigating factors that could justify inferior outcomes by transplant centers under specific circumstances. Failure to reach consensus on such a mechanism would result in continued risk-averse behavior by transplant centers undermining innovation and hampering advancement of the field of transplantation and ultimately compromising patient care," said Dr. Wang.

Abstract title:

Donor and Recipient Risk Aversion in Liver Transplantation

AASLD is the leading medical organization for advancing the science and practice of hepatology. Founded by physicians in 1950, AASLD's vision is to prevent and cure liver diseases. This year's Liver Meeting®, held in San Francisco, California, November 4 – 8, will bring together more than 8,000 researchers from 55 countries.

A press room will be available from November 5 at the annual meeting. For copies of abstracts and press releases, or to arrange researcher interviews, contact Gregory Bologna at 703-299-9766.

Press releases and all abstracts are available online at

This release was issued through The Xpress Press News Service, merging e-mail and satellite distribution technologies to reach business analysts and media outlets worldwide. For more information, visit

SOURCE American Association for the Study of Liver Diseases (AASLD)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tibotec to Present Final Safety and Efficacy Results From Phase 2b PILLAR Study of Once-Daily TMC435 in Late-Breaker at AASLD
2. Study Shows Efficacy of C1-Esterase Inhibitor Concentrate in Treating Acute Attacks of Hereditary Angioedema in Children and Adolescents
3. New 12 Week, Interferon-Free Treatment Arms Added to All-Oral Combination Study of PSI-7977 and Daclatasvir (BMS-790052) for HCV Genotype 1
4. Study Shows New Medication Effectively Treats Underlying Cause of Cystic Fibrosis
5. Pharmacodynamic Data from Syndax Pharmaceuticals ENCORE 301 Study in Advanced Breast Cancer to be Highlighted at the AACR Molecular Targets and Cancer Therapeutics Conference 2011
6. Inovio Pharmaceuticals Cervical Dysplasia And Cancer Treatment Highlighted as One of 10 Promising Therapeutic Vaccines; Phase II Clinical Study Currently Enrolling
7. Cytogel Pharma, LLC. Announces Presentation at the American Society of Anesthesiologists meeting in Chicago on October 18, 2011, Describing Results From its First Human Study, Part of the Phase I Program for Cyt-1010
8. Idenix to Host Conference Call Discussing Third Quarter and Nine Month 2011 Financial Results and Announces Presentations at the American Association for the Study of Liver Diseases Meeting (AASLD)
9. ADVENTRX and FDA Reach Agreement on Pivotal Study for ANX-514
10. FTC Study Finds that in FY 2011, Pharmaceutical Industry Continued to Make Numerous Business Deals that Delay Consumers Access to Lower-Cost Generic Drugs
11. Anthera Announces Last Patient Enrolled in PEARL-SC Study
Post Your Comments:
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at ...
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
(Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
Breaking Medicine Technology:
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance ... management, will showcase a range of technology and learning solutions at the 68th ... and Expo to be held October 14–18, 2017 at the Mandalay Bay Resort ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare events ... Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the ... The annual award competition recognizes editorial and design excellence across a range of sectors. ...
Breaking Medicine News(10 mins):